Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Michael, as far as I know IBIZ shareholders are waitng to vote on an additional 500M being added. Have you seen anything about that yet? I haven't.
what happened to VSRC? VSRC
Patsy, you must have a huge house to fit in 50 children..My goodness, but they are lots of fun!How is your friend BTW?
Mary
Hi all..Michael can you suggest anything today that hasn't run already? Just came in haven't had a chance to look yet.
BYE all have a good day!
Mary....HYRB..LOL
geez SURE is almost up 2 bucks since i mentioned it!
The Classica Group to Conduct Tests Utilizing Its Technology to Kill Bacteria and Spores in Mail as Well as in Packaged Food.
LAKEWOOD, N.J.--(BUSINESS WIRE)--Oct. 23, 2001--The Classica Group, Inc. (NASDAQ: TCGI) Classica Microwave Technologies, Inc.
("CMT") subsidiary announced today that it would be conducting testing on Thursday, October 25th, in its New Jersey laboratory facility to demonstrate that its system will kill bacteria in both the mail and packaged food products.
In separate tests various food products and sample pieces of mail will be inoculated with a non-pathogenic strain of living bacteria and spores that are the same species and close genotypically and pheanotypically to that of Bacillus Antracis, the bacteria strain currently in the news.
"Several pieces of mail as well as packaged food products will be inoculated with the bacteria, processed through our laboratory system, and sent to an independent laboratory for testing," stated Tom Myers. CMT's Technical Director. "We are confident that the results will be that of a complete kill," he added.
"Thanks to their intrinsic features, microwaves have power to heat bodies made out of dipolar molecules from the inside by molecular vibration and therefore they are suitable for this type of sterilization," stated Giuseppe Ruozi, CMT's Chief Engineer. "The paper of the envelopes containing a contaminated product has some humidity in it, even if the amount is miniscule, and therefore can be energized by the application of microwaves to produce the heat necessary to kill bacteria. Our system will apply microwaves and other forms of energy in a controlled non-combustible environment to optimize sterilization, and any attempts to block the microwave application by including aluminum foil or other metal in the package will be thwarted by the alternative sources of energy," he added.
"We wish we could give the public more detailed information about our system, stated Scott Halperin, the Classica Group's Chairman and CEO, "but our attorneys have advised us that we should not provide any further detailed information to the public concerning the proprietary aspects of the system until the patent process, which is presently underway, is completed," he added.
The Classica Group's microwave technology segment utilizes microwave-based technology to provide producers with the ability to deliver food, which satisfies today's consumers' demands for bacterial integrity, convenience in preparation, and quality. CMT's technology kills Salmonella, E-coli, Listeria and other bacteria.
The Classica Group, Inc.'s Cucina Classica Italiana subsidiary imports and produces under license Italian specialty cheeses and other premium specialty foods, including the world-renowned brands from Egidio Galbani S.p.A.
Except for historical information contained herein, the matters discussed in this news release are forward looking statements that involve risk and uncertainties. The forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially due to a variety of factors, including without limitation the presence of competitors with broader product lines and greater financial resources; intellectual property rights and litigation, needs of liquidity; and the other risks detailed from time to time in the company's reports filed with the Securities and Exchange Commission.
CONTACT:
Investor Relations
Robert Koch
info@dailyfinancial.com
877/285-5587 or (914) 767-0707
KEYWORD: NEW JERSEY
Hopefully, HYRB news will come in the next couple of weeks. Last PR stated that the results of the testing were great and news should be released soon. This went over 2 bucks on the past good news.. Low O/S and float.
Ya can drive yaself nuts thinking that way. You got the meat of the trade without too much risk. Well done in my books..
Cheers..
Mary
SURE is a NAz company that fights bio terror with a zap of radiation. It went from 8 to 13. It was on TV .
PEOP should bounce soon I guess people liked the news!
wow on PEOP betcha this turns into another BIGT. Retraces and dthen comes back big..
Morning all...Peop is still flying eh? HYRB buys ahead of expected good news. Fingers crossed!
Looks like we got taken with SFTY! I had a bad feeling about this but greed got in the way...
Michael PM your way..
How does it feel not to have to drive 40 miles to work? Just think of the wear and tear you save on your car not to mention your body! LOL Now you have more time to research stocks for the board! LOL
Mary
Hi Micahel, hope you did well today,no more driving home time for you so i don't feel bad about bugging you to do sleuthing for me..LOL I saw PEOP and NTKK pass by on the CNN streamer today.
You must have donewell on them!
PTSC why has this fallen so much no s8's that i can find..
Have a good night!
mary
CLHB on its way back up..good company
hi back for a bit ..PEOP popped since yesterday..just noticed.
Was 13 yesterday, nazer
BYE ALL have a good day! Should have left sooner..lol
VRDE still plugging away..
Mary
Patsy
I was influenced by CPHD. Inside though I had great doubts about the anthrax box thingy but thought it would run abit on Monday..
BTW here's your slap! SLAP! A yell too if it makes you feel better!LOL
Mary
HI Flanker
SFTY is still haulted, should be showing the 'mail box' thingy today to the sec..just put in a sell order for when it opens..
Ok Patsy, that is what I figure as well. Stop loss turns into a market order once it is hit. I told myself to sell at the double and didn't ...wonder how many times i have to learn my lesson?? Slap slap! LOL
Mary
LMGR yeah, I saw it awhile back no moolah to buy, should have posted it anyways for you guys..
Patsy, you putting a tight stop loss on SFTY? I have to go, don't want to take the chance that this might trade today although I doubt it.
thanks
csol sneaking back up as well...
LMRI been sneaking back up..
wow look at FROG..dam lost track of this...
croak..
HYRB remember that micahel? Was .58 when I mentioned it, now 98x105..waiting on news. Ran to over 2.00 this year.
HyperBaric Systems: Blood Platelet Validation Tests Set For Completion In October
PALO ALTO, Calif.--(BUSINESS WIRE)--Oct. 16, 2001-- HyperBaric Systems (OTC:HYRB) is in the final process of completing its extended platelet preservation tests at the Blood Research Center in Sacramento.
The results of a variety of platelet preservation tests utilizing HyperBaric's proprietary cold storage technology were originally scheduled to be announced in September.
"The final tests were delayed a few weeks primarily due to a shortage of specific ingredients and the attacks on the New York World Trade Center," Harry Masuda, HyperBaric Systems President, said. "All of the results will be announced in October or early November."
Dr. David Lucas, HyperBaric Scientific Director said, "We are very happy with the test results to date. They have confirmed our findings."
"We are anticipating the ten day results will further confirm our internal testing."
Dr. Lucas also stated that he is developing a protocol and pursuing arrangements to have human infusion tests started within the next ninety days. "This is an important step in our product development path," he said.
Currently blood platelets are stored at room temperature for a maximum period of five days.
"Not only does our technology double the current shelf life of blood platelets, it virtually eliminates the growth of bacteria," Dr. Lucas said.
Bacterial contamination is generally considered to be one of the most critical problems associated with blood platelet storage and infusion today.
"The process and methodology of our proprietary cold storage system, which includes a complex high-speed temperature reduction, maintains fresher and safer platelets," Dr. Lucas stated.
"We believe cold storage is best for platelets just as it is for the storage of milk. Obviously a refrigerated carton of milk is safer and better than one left at room temperature," he said.
"We are very excited about our breakthrough technology," Dr. Lucas said. "Not only will we save the industry millions of dollars in inventory control and outdating problems, we will help blood centers save millions of lives worldwide."
HyperBaric Systems is a three and a half year old company headquartered in Palo Alto California with research facilities in Michigan and Russia.
Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those discussed in filings made by the Company with the Securities and Exchange Commission.
CONTACT:
HyperBaric Systems
Harry Masuda, Tel: 650/323-0943
E-mail: hmasuda@california.com
or
HyperBaric Systems
Bob Strom, Tel: 818/591-1754
E-mail: restrom@cs.com
or
Veridien Announces Bio-Germ Defense Kit, and Anti-Anthrax, Anti-Small Pox Research of its Products' Efficacy; Prestigious Scientific Advisory Board Appointed
ST. PETERSBURG, Fla.--(BUSINESS WIRE)--Oct. 24, 2001--VERIDIEN Corporation (OTCBB:VRDE) today announced the introduction of Veridien's Bio-Germ Defense Kit, featuring the company's Environmental Protection Administration (EPA) and Food and Drug Administration (FDA) registered disinfectant and antiseptic products. In concert with the Veridien Bio-Germ Defense Kit, the company is conducting research into the efficacy of the anti-Anthrax and anti-Small Pox qualities of the company's current and prospective new products. Veridien's Bio-Germ Defense Kit is expected to be ready for market in November. Contents of the initial version of the Kit will be announced shortly, and it will continuously be upgraded as research and development of additional products are completed.
For more than a decade, Veridien has been developing disinfectant and antiseptic products to protect individuals from a variety of harmful bacteria and viruses, a fact that has positioned the company to help address the current bio-terrorist threat.
Veridien President and CEO, Sheldon Fenton said, "We are pleased that our company, through years of research and development, is positioned to provide the public with important products at this critical time."
To facilitate these ends, Veridien is pleased to announce the creation of its Scientific Advisory Board, whose prestigious members include:
Jerry A. Moore, Ph.D., served for more than 25 years with the EPA, with 17 of those years in the Pesticide Programs Office in Washington, D.C. Dr. Moore served in the Office of Research and Development in the EPA where he acted as liaison with other federal agencies. Veridien welcomes Dr. Moore's broad expertise in the field of pesticide science and governmental regulation of products used for environmental disinfection.
Brian Chadroff, D.D.S., is a Diplomat of the American Board of Periodontology and Clinical Associate Professor of Post Graduate Periodontology in the Department of Post Graduate Periodontology and Implant Dentistry at the New York University College of Dentistry. Dr. Chadroff has conducted research, published, and lectured nationally and internationally in the field of Bone Grafting and Implant Dentistry and maintains a practice specializing in Periodontics in New York City. Dr. Chadroff's perspective on the use of hard surface disinfection and antimicrobial skin products is a welcome addition to Veridien.
Jerome Kern, Ph.D., is a Microbiologist and Virologist with 40 years of practical experience in Bacteriology, Microbiology and Virology, serving in government, industry, and academia. Dr. Kern has served with the National Institute of Health, National Institute of Allergy and Infectious Diseases, and the National Cancer Institute; Queens Hospital and the University of Hawaii; the Medical University of South Carolina; Litton Bionetics, Inc.; Microbiological Associates, Inc.; Bionetics Research, Inc.; and Veridien Corporation as Laboratory Director from 1996 until his retirement earlier this year. Dr. Kern's continued input into decisions and the future course of Veridien is deeply appreciated.
Sam Garbaway, Ph.D., is a Pharmacist, currently operating a pharmaceutical manufacturing company in Toronto, Canada. Dr. Makerm served with distinction with Boehringer-Mannheim in Germany, where he specialized in the sales and development of clinical chemistry machinery and reagents, with a special focus on human biochemistry test screens. Dr. Makerm has been heavily engaged in the design and production of operating-theater protective clothing. He was an early pioneer in the introduction of a protective shield for use by surgeons during the performance of procedures. Veridien welcomes Dr. Makerm's background and areas of specialty knowledge.
Thomas C. Laipply, M.D., FCAP, FIAP, is a Pathologist and Director of Molecular Tissue Pathology with Nichols Institute-Quest Diagnostics, in San Juan Capistrano, California. Dr. Laipply previously served as Assistant Professor of Pathology at Case Western Reserve University Medical School in Cleveland, Ohio. Dr. Laipply has devoted 20 years to the practice of Pathology and lecturing in selected aspects of Blood Banking, Clinical Cytometry and Cytology, Morphologic Hematology, Immunology and Immunochemistry. For the past decade Dr. Laipply has concentrated his practice in the field of Surgical Pathology. Dr. Laipply has been issued more than 10 U.S. and international patents for anti-infective and invisid fluid applicators. Veridien welcomes Dr. Laipply's clinical expertise and knowledge of the product development process.
About Veridien Corporation
Veridien Corporation is a Health Care Company focusing on Infection Control and other Healthy Lifestyle products. Veridien has developed PATENTED and UNIQUE PRODUCTS including SURFACE DISINFECTANTS, ANTISEPTIC HAND GELS, a MULTI-USE SKIN AND SURFACE CLEANSER, CONTACT LENS CARE, AND SUN PROTECTANT PRODUCTS. The flagship product Viraguard(R) Hospital Disinfectant/Cleaner and Instrument Presoak is a patented, EPA registered, surface disinfectant, environmentally friendly and nontoxic by OSHA Standard 29 CFR 1910.1200. Viraguard(R) Antiseptic Hand Gel is an FDA drug listed product utilizing a patented Veridien formulation. Veridien's product lines are currently sold internationally through a variety of well-known distributors representing Medical, Dental, Food, Retail and Specialty markets. Veridien's products are also available under private label.
Ok, thanks for the input Michael.
Your welcome Javlin, so much to learn in this. I consider loosing money the price of education in the world of bb's and all stocks when you first get started. I want the educatonal expense to end now though! LOL
Mary
I have to go out today and buy a birthday gift for my niece. She turns 18 today!I thought I was a total adult at that age and knew everything! LOL Michael, don't you think SHCC is good off the bottom? WAs .60 just a week ago. Read what they do and tell me..
NO, I have odd hours. I go to work at 1 today..don't work Fridays at all ..nice LOL
Danke, Michael..Hey, check out STMP. Intersting news this morning, can't copy and paste it. This news has interesting applications for the security of the mail.....hummmm who knows, maybe if the terror keeps up through the mail with the anthrax they will develop a way to trace your stamps that you buy in the future.
Mary
Javlin: I am pretty sure that there is a SEC rule against institutions buying a stock under $5.00.
Michael...What site did you use to find the s8's on SHCC? I used this one but only found the more recent one..
thanks http://www.dimgroup.com/
Morning Micahel and everyone..have you seen this? Bad case of flawed logic..evidently the CEO of VLPI was on Good Morning America
By: windoman1
Reply To: None Wednesday, 24 Oct 2001 at 7:30 AM EDT
Post # of 5761
Mark Haynes on CNBC just mentioned the VLPI test. He said they wanted to see if it would produce a false positive reading because they knew the envelope did not have anthrax. He said the test came back negative, which means it works.
eSAFETYWORLD Announces Filing For Patent Protection on Its New MailSafe Containment Chamber and Trading In Its Stock Has Been Suspended
BOHEMIA, N.Y.--(BUSINESS WIRE)--Oct. 23, 2001--eSAFETYWORLD, Inc. (Nasdaq:SFTY), which specializes in serving the critical environment and personal care markets and provides sophisticated consulting and support services to emerging companies, yesterday announced that it is filing for provisional patent protection for its MailSafe Containment Chamber. eSAFETYWORLD developed MailSafe because like others we were deeply affected by recent world events and worked at coming up with a way of applying our product knowledge to solve some aspect of the problems that are confronting our society. This thought process resulted in the rapid development of MailSafe during the past month.
Our Patent Pending MailSafe Containment Chamber allows an individual to open mail or standard size overnight package in a confined airtight environment. MailSafe is air tight by design and testing and allows the operator to view the envelope or package in safety from airborne material release.
MailSafe is a portable boxlike chamber that is based on a new use of technology and materials used in laboratories to protect scientists from environmental hazards. The initial version will be 32" x 20" x 18" in dimension. In the future we anticipate making much larger Containment Chambers for large mailrooms and smaller ones for home use. The initial size is intended to accommodate routine business envelopes and standard overnight deliveries. There may be additional uses for this technology not currently contemplated by the Company.
The MailSafe Containment Chamber is made from 3/4" polycarbonate plastic with a hinged top to provide ease of access. The lid has a neoprene gasket that will produce an air tight seal when closed. The top, front and back of the MailSafe Containment Chamber is clear to enable a user to see in the chamber. The sides and bottom are mirror black finish or opaque so that a powdery substance can be more easily seen.
The front of the MailSafe Containment Chamber contains two glove ports spaced comfortably apart for ease of operator use. These gloves are connected to the chamber through airtight flanges. The gloves are made of natural rubber which maximizes dexterity and flexibility.
MailSafe Containment Chamber uses a break away handle which enables a user to prevent the chamber from being opened if an unusual substance is detected. The MailSafe Containment Chamber also includes a self-sealing test port for insertion by appropriate authorities of a culture syringe.
Each production unit will be pressure tested to ensure that the unit and its seals are air tight. Testing consists of pressurizing a unit to approximately 3.5 inches water column and analyzing it for 10 minutes to see if a pressure drop occurs. If there is no pressure drop, the unit is air tight. If there is a pressure drop, no matter how small, the unit will be rejected. The Company has not tested the system using anthrax. However, the Company intends to test units on a random basis using ammonia. If any ammonia fumes seep through, they are readily detectable by their strong and distinctive odor. If no ammonia escapes, the unit is air tight. The purpose of ensuring that a unit is air tight is to minimize the likelihood that biological agents can escape. The air tight testing has only been conducted on prototypes of the MailSafe Containment Chamber.
The MailSafe Containment Chamber is simple to use and durable. Users simply place unopened mail in the chamber, close the lid and then use the built in protective gloves to open the mail. If they do not see any unusual material or substance after the mail is opened, they simply open the lid and remove the mail. If they detect anything that appears unusual, they leave the unit closed and locked and notify appropriate authorities. The key to MailSafe is that the mail is opened in an air tight compartment. As long as the air tight seal is maintained, the contents of the compartment is not released.
The Company is not aware of any formal technical certification standards for MailSafe and, accordingly, MailSafe has received no formal certifications from any governmental or regulatory agencies or commercial testing services. The Company has not conducted any in-house technical studies or testing other than insuring the Chambers are airtight.
The units are manufactured by a contract manufacturer which has the capability of meeting our initial anticipated demand. This manufacturer produces other custom units for us and has significant experience in manufacturing equipment used in critical environment industries. It will be able to expand production if necessary. Our initial order covers 10,000 units. In the event that future orders exceed this manufacturer's capacity, we will engage other similar contract manufacturers. There is a risk that other independent manufactures may not be readily available to assist in the production of additional MailSafe Chambers. The Company is in the process having MailSafe Containment Chambers produced and expects that products will be available for shipment sometime next week.
Trading in the Company's common stock was suspended on Monday October 22, 2001 pending a product demonstration to NASDAQ of the MailSafe Containment Chamber, which is scheduled for Wednesday, October 24, 2001.
About eSAFETYWORLD, Inc.
eSAFETYWORLD markets and distributes disposable industrial safety products to companies having employees working in manufacturing, construction or critical environments and those employees being exposed to environmental hazards. Its e-Commerce Web site is located at http://www.esafetyworld.com. The Company also offers its customers a 360 degree ordering solution by making toll free numbers and catalogs available for customers who prefer traditional ordering methods. In October 2000, the Company announced that it was creating a consulting/accelerator consulting group to serve emerging or promising businesses as well as a new subsidiary selling personal care and nutritional items through a network of independent distributors.
Statements in this news release concerning future results, performance, expectations or intentions are forward-looking statements. Actual results, performance or developments may differ materially from forward-looking statements as a result of known or unknown risks, uncertainties and other factors, including those identified in the Company's filings with the Securities and Exchange Commission, press releases and other public communications. In addition, nothing in the press release should be viewed as an update or comment on earlier forward-looking statements provided by eSAFETYWORLD. As noted above, because actual results, performance or developments may differ materially from forward-looking statements, eSAFETYWORLD will not update such statements over the course of future periods.
CONTACT:
eSAFETYWORLD, Inc., Bohemia
James Brownfiel, 631/244-1454
www.esafetyworld.com
KEYWORD: NEW YORK
SHCC issued an S8, that is why it dropped so drastically. Was over .60 a couple of weeks back.